Clinical Trial Detail

NCT ID NCT02829840
Title Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

acute myeloid leukemia

myelodysplastic syndrome

myelodysplastic/myeloproliferative neoplasm

Therapies

Azacitidine + Ponatinib

Age Groups: senior adult

Additional content available in CKB BOOST